Safety Study of MGD009 in B7-H3-expressing Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 25, 2019

Study Completion Date

November 25, 2019

Conditions
MesotheliomaBladder CancerMelanomaSquamous Cell Carcinoma of the Head and NeckNon Small Cell Lung CancerClear Cell Renal Cell CarcinomaOvarian CancerThyroid CancerBreast CancerPancreatic CancerProstate CancerColon CancerSoft Tissue Sarcoma
Interventions
BIOLOGICAL

MGD009

B7-H3 x CD3 DART protein

Trial Locations (20)

2010

Saint Vincent's Hospital Sydney, Darlinghurst

2050

Chris O'Brien Lifehouse, Camperdown

3084

Austin Health, Heidelberg

4102

Princess Alexandra Hospital, Woolloongabba

6009

Linear Clinical Research, Nedlands

10016

New York University, New York

10032

Columbia University Medical Center, New York

19104

Penn Presbyterian Medical Center, Philadelphia

20007

Georgetown University, Washington D.C.

22034

Virginia Cancer Specialists, Fairfax

28078

Carolina BioOncology Institute, Huntersville

37232

Henry-Joyce Cancer Center, Nashville

75230

Mary Crowley Cancer Research Center, Dallas

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

90095

UCLA, Los Angeles

94143

University of California - San Francisco, San Francisco

94304

Stanford University School of Medicine, Palo Alto

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

M5G1Z5

Princess Margaret Cancer Centre, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MacroGenics

INDUSTRY